Movement disorders: therapeutic role of vitamin E.
Cadet
J L
JL
Unit on Cellular and Molecular Neurotoxicology, NIDA, ARC, Baltimore, MD 21224.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects*; D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000378:metabolism; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D016627:Oxidopamine / Q000009:adverse effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014810:Vitamin E / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D005609:Free Radicals; D014810:Vitamin E; D016627:Oxidopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine